SUPPLEMENT

Q4 2020 — Financial disclosures

Q4 2020PDF · 13 pages1.1 MB
Merck & Co., Inc.
Financial Highlights Package
Fourth Quarter 2020
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 4Q20 ........................3
Table 2b: GAAP to Non-GAAP Reconciliation Dec YTD 20.............4
Table 2c: GAAP to Non-GAAP Reconciliation 4Q19.........................5
Table 2d: GAAP to Non-GAAP Reconciliation Dec YTD 19 .............6
Table 3: 	Sales – Current Year and Prior Year by Quarter ...............7
Table 3a: Sales – U.S. / Ex- U.S. 4Q20 ............................................8
Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 20. ................................9
Table 3c: Sales – Pharmaceutical Geographic Split .......................10
Table 4: Other (Income) Expense .................................................11
Table 5: Non-GAAP Reporting Changes........................................12
Tables 1 and 1a in the Financial Highlights Package reflect updated averages shares for 4Q 2020.

-- 1 of 13 --

Sales 	12,514	$ 	11,868	$ 	5% 	47,994	$ 	46,840	$ 	2%
Costs, Expenses and Other
Cost of sales (1) 5,532 	3,669 	51% 	15,485 	14,112 	10%
Selling, general and administrative (1) 3,086 	2,888 	7% 	10,468 	10,615 	-1%
Research and development (1) 5,838 	2,548 	* 	13,558 	9,872 	37%
Restructuring costs (2) 309 	194 	59% 	578 	638 	-9%
Other (income) expense, net (1) (258) 	(223) 	16% 	(886) 	139 	*
(Loss) Income Before Taxes 	(1,993) 	2,792 	* 	8,791 	11,464 	-23%
Income Tax Provision (1) 99 	428 	1,709 	1,687
Net (Loss) Income 	(2,092) 	2,364 	* 	7,082 	9,777 	-28%
Less: Net Income (Loss) Attributable to Noncontrolling Interests (1) 2 	7 	15 	(66)
Net (Loss) Income Attributable to Merck & Co., Inc. 	(2,094)	$ 	2,357	$ 	* 	7,067	$ 	9,843	$ 	-28%
(Loss) Earnings per Common Share Assuming Dilution (3) (0.83)	$ 	0.92	$ 	* 	2.78	$ 	3.81	$ 	-27%
Average Shares Outstanding Assuming Dilution (3) 2,530 	2,559 	2,541 	2,580
Tax Rate (4) -5.0% 	15.3% 	19.4% 	14.7%
* 100% or greater
(4) The effective income tax rates for the fourth quarter and the full year of 2020 include the unfavorable impact of charges for the acquisitions of VelosBio Inc. and OncoImmune for
which no tax benefits were recognized. The effective income tax rates for the fourth quarter and the full year of 2019 include the unfavorable impact of a charge for the acquisition of
Peloton Therapeutics, Inc. for which no tax benefit was recognized and the favorable impact of product mix. The effective income tax rate for the full year of 2019 also reflects a net
tax benefit of $364 million related to the settlement of certain federal income tax matters.
4Q19 Full Year
2020
Full Year
2019
(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.
(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.
(3) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming
dilution as the effect would have been anti-dilutive. The shares previously disclosed were the average common shares assuming dilution; however, the loss per common share was
appropriately calculated based on the average common shares excluding potential dilutive shares. The shares figure has been updated to reflect the average common shares
outstanding that were used in the loss per common share calculation.
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
4Q20
1

-- 2 of 13 --

. 	.
Sales 	12,057	$ 	10,872	$ 	12,551	$ 	12,514	$ 	47,994	$ 	10,816	$ 	11,760	$ 	12,397	$ 	11,868	$ 	46,840	$ 	5% 	2%
Costs, Expenses and Other
Cost of sales 	3,312 	3,159 	3,481 	5,532 	15,485 	3,052 	3,401 	3,990 	3,669 	14,112 	51% 	10%
Selling, general and administrative 	2,555 	2,378 	2,450 	3,086 	10,468 	2,425 	2,712 	2,589 	2,888 	10,615 	7% 	-1%
Research and development 	2,209 	2,123 	3,390 	5,838 	13,558 	1,931 	2,189 	3,204 	2,548 	9,872 	* 	37%
Restructuring costs 	72 	83 	114 	309 	578 	153 	59 	232 	194 	638 	59% 	-9%
Other (income) expense, net 	71 	(390) 	(312) 	(258) 	(886) 	188 	140 	35 	(223) 	139 	16% 	*
Income (Loss) Before Taxes 	3,838 	3,519 	3,428 	(1,993) 	8,791 	3,067 	3,259 	2,347 	2,792 	11,464 	* 	-23%
Income Tax Provision 	619 	509 	483 	99 	1,709 	205 	615 	440 	428 	1,687
Net Income (Loss) 	3,219 	3,010 	2,945 	(2,092) 	7,082 	2,862 	2,644 	1,907 	2,364 	9,777 	* 	-28%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	- 	8 	4 	2 	15 	(53) 	(26) 	6 	7 	(66)
Net Income (Loss) Attributable to Merck & Co., Inc. 	3,219	$ 	3,002	$ 	2,941	$ 	(2,094)	$ 	7,067	$ 	2,915	$ 	2,670	$ 	1,901	$ 	2,357	$ 	9,843	$ 	* 	-28%
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.26	$ 	1.18	$ 	1.16	$ 	(0.83)	$ 	2.78	$ 	1.12	$ 	1.03	$ 	0.74	$ 	0.92	$ 	3.81	$ 	* 	-27%
Average Shares Outstanding Assuming Dilution (1) 	2,547 	2,536 	2,538 	2,530 	2,541 	2,603 	2,588 	2,572 	2,559 	2,580
Tax Rate 	16.1% 	14.5% 	14.1% 	-5.0% 	19.4% 	6.7% 	18.9% 	18.7% 	15.3% 	14.7%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. The shares
previously disclosed were the average common shares assuming dilution; however, the loss per common share was appropriately calculated based on the average common shares excluding potential dilutive shares. The shares figure has
been updated to reflect the average common shares outstanding that were used in the loss per common share calculation.
2Q 	3Q 	4Q 	Full Year 	4Q 	Full Year	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2020 	2019 	% Change
2

-- 3 of 13 --

Cost of sales 	5,532	$ 	1,855 	44 	260 	2,159 	3,373	$
Selling, general and administrative 	3,086 	287 	10 	297 	2,789
Research and development 	5,838 	13 	16 	3,161 	3,190 	2,648
Restructuring costs 	309 	309 	309 	-
Other (income) expense, net 	(258) 	(2) 	(3) 	(5) 	(253)
(Loss) Income Before Taxes 	(1,993) 	(2,153) 	(379) 	(3,418) 	(5,950) 	3,957
Income Tax Provision (Benefit) 	99 	(423) (3) (22) (3) (61) (3) (506) 	605
Net (Loss) Income 	(2,092) 	(1,730) 	(357) 	(3,357) 	(5,444) 	3,352
Net (Loss) Income Attributable to Merck & Co., Inc. 	(2,094) 	(1,730) 	(357) 	(3,357) 	(5,444) 	3,350
(Loss) Earnings per Common Share Assuming
Dilution (0.83)	$ 	(0.68) 	(0.15) 	(1.32) 	(2.15) 	1.32	$
Tax Rate 	-5.0% 	15.3%
Only the line items that are affected by non-GAAP adjustments are shown.
Table 2a
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items (4)
Adjustment
Subtotal
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FOURTH QUARTER 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
(1) Amount included in cost of sales primarily reflects a $1.6 billion intangible asset impairment charge related to ZERBAXA and $274 million for the amortization of intangible assets recognized
as a result of business acquisitions. Amount included in selling, general and administrative expenses reflects $244 million related to the company's planned spin-off of Organon & Co., and other
acquisition and divestiture-related costs.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Amount included in cost of sales represents a charge for the discontinuation of COVID-19 vaccine development programs. Amount included in research and development represents the
charges of $2.7 billion for the acquisition of VelosBio Inc., $462 million for the acquisition of OncoImmune and $45 million for the discontinuation of COVID-19 vaccine development programs.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
3

-- 4 of 13 --

Cost of sales 	15,485	$ 	2,718 	175 	260 	3,153 	12,332	$
Selling, general and administrative 	10,468 	935 	47 	982 	9,486
Research and development 	13,558 	1 	83 	4,243 	4,327 	9,231
Restructuring costs 	578 	578 	578 	-
Other (income) expense, net 	(886) 	50 	(20) 	30 	(916)
Income Before Taxes 	8,791 	(3,704) 	(883) 	(4,483) 	(9,070) 	17,861
Income Tax Provision (Benefit) 	1,709 	(671) (3) (81) (3) (303) (3) (1,055) 	2,764
Net Income 	7,082 	(3,033) 	(802) 	(4,180) 	(8,015) 	15,097
Net Income Attributable to Merck & Co., Inc. 	7,067 	(3,033) 	(802) 	(4,180) 	(8,015) 	15,082
Earnings per Common Share Assuming Dilution 	2.78	$ 	(1.19) 	(0.32) 	(1.65) 	(3.16) 	5.94	$
Tax Rate 	19.4% 	15.5%
Only the line items that are affected by non-GAAP adjustments are shown.
Table 2b
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FULL YEAR 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
(4) Amount included in cost of sales represents a charge for the discontinuation of COVID-19 vaccine development programs. Amount included in research and development represents the
charges for the acquisitions of VelosBio Inc. and OncoImmune, a charge for the discontinuation of COVID-19 vaccine development programs, and upfront payments related to license and
collaboration agreements.
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items (4)
Adjustment
Subtotal Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects a $1.6 billion intangible asset impairment charge related to ZERBAXA and $1.1 billion for the amortization of intangible assets recognized as
a result of business acquisitions. Amount included in selling, general and administrative expenses reflects $710 million related to the company's planned spin-off of Organon & Co.,
approximately $95 million of costs related to the acquisition of ArQule, Inc., and other acquisition and divestiture-related costs. Amount included in other (income) expense, net, primarily reflects
expenses related to an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-
Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related
costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition.
4

-- 5 of 13 --

Cost of sales 	3,669	$ 	325 	90 	415 	3,254	$
Selling, general and administrative 	2,888 	44 	1 	45 	2,843
Research and development 	2,548 	166 	11 	177 	2,371
Restructuring costs 	194 	194 	194 	-
Other (income) expense, net 	(223) 	(37) 	7 	(30) 	(193)
Income Before Taxes 	2,792 	(498) 	(285) 	(18) 	(801) 	3,593
Income Tax Provision (Benefit) 	428 	(55) (3) (49) (3) (76) (4) (180) 	608
Net Income 	2,364 	(443) 	(236) 	58 	(621) 	2,985
Net Income Attributable to Merck & Co., Inc. 	2,357 	(443) 	(236) 	58 	(621) 	2,978
Earnings per Common Share Assuming Dilution 	0.92	$ 	(0.17) 	(0.09) 	0.02 	(0.24) 	1.16	$
Tax Rate 	15.3% 	16.9%
Only the line items that are affected by non-GAAP adjustments are shown.
Non-GAAP
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FOURTH QUARTER 2019
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2c
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items
Adjustment
Subtotal
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects $306 million of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $12 million of
intangible asset impairment charges. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and certain other costs related to business
acquisitions and divestitures. Amount included in research and development expenses primarily reflects $164 million of in-process research and development (IPR&D) impairment charges.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Primarily reflects an $86 million tax benefit related to the reversal of tax reserves established in conjunction with the divestiture of Merck's Consumer Care business in 2014 as a result of the
lapse in the statute of limitations.
5

-- 6 of 13 --

Cost of sales 	14,112	$ 	2,126 	251 	2,377 	11,735	$
Selling, general and administrative 	10,615 	126 	34 	160 	10,455
Research and development 	9,872 	145 	4 	993 	1,142 	8,730
Restructuring costs 	638 	638 	638 	-
Other (income) expense, net 	139 	284 	55 	339 	(200)
Income Before Taxes 	11,464 	(2,681) 	(927) 	(1,048) 	(4,656) 	16,120
Income Tax Provision (Benefit) 	1,687 	(493) (3) (155) (3) (380) (5) (1,028) 	2,715
Net Income 	9,777 	(2,188) 	(772) 	(668) 	(3,628) 	13,405
Less: Net (Loss) Income Attributable to
Noncontrolling Interests (66) 	(89) 	(89) 	23
Net Income Attributable to Merck & Co., Inc. 	9,843 	(2,099) 	(772) 	(668) 	(3,539) 	13,382
Earnings per Common Share Assuming Dilution 	3.81	$ 	(0.82) 	(0.30) 	(0.26) 	(1.38) 	5.19	$
Tax Rate 	14.7% 	16.8%
Only the line items that are affected by non-GAAP adjustments are shown.
Table 2d
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FULL YEAR 2019
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
(5) Primarily reflects a $364 million net tax benefit related to the settlement of certain federal income tax matters, an $86 million tax benefit related to the reversal of tax reserves established in
conjunction with the divestiture of Merck's Consumer Care business in 2014 as a result of the lapse in the statute of limitations, and a $117 million tax charge related to the finalization of treasury
regulations associated with the 2017 enactment of U.S. tax legislation.
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items (4)
Adjustment
Subtotal Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects $1.4 billion of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $705 million of
intangible asset impairment charges, including $612 million related to SIVEXTRO. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and
certain other costs related to business acquisitions and divestitures, including costs related to the acquisition of Antelliq Corporation. Amounts included in research and development expenses
primarily reflect $172 million of in-process research and development (IPR&D) impairment charges, partially offset by a reduction in expenses related to a decrease in the estimated fair value
measurement of liabilities for contingent consideration. Amount included in other (income) expense, net primarily reflects goodwill and intangible asset impairment charges related to certain
businesses in the Healthcare Services segment and expenses related to an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty
income related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Amount included in research and development represents the charge related to the acquisition of Peloton Therapeutics, Inc.
6

-- 7 of 13 --

1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $12,057 	$10,872 	$12,551 	$12,514 	$47,994 	$10,816 	$11,760 	$12,397 	$11,868 	$46,840 	5 	5 	2 	4
PHARMACEUTICAL 	10,655 	9,679 	11,320 	11,367 	43,021 	9,663 	10,460 	11,095 	10,533 	41,751 	8 	6 	3 	4
Oncology
Keytruda 	3,284 	3,388 	3,715 	3,993 	14,380 	2,269 	2,634 	3,070 	3,111 	11,084 	28 	27 	30 	30
Alliance Revenue – Lynparza (2) 145 	178 	196 	206 	725 	79 	111 	123 	132 	444 	56 	53 	63 	62
Alliance Revenue – Lenvima (2) 128 	151 	142 	158 	580 	74 	97 	109 	124 	404 	28 	26 	44 	43
Emend 	43 	33 	39 	31 	145 	117 	121 	98 	53 	388 	-42 	-42 	-63 	-62
Vaccines (3)
Gardasil / Gardasil 9 	1,097 	656 	1,187 	998 	3,938 	838 	886 	1,320 	693 	3,737 	44 	41 	5 	6
ProQuad / M-M-R II / Varivax 	435 	378 	576 	488 	1,878 	496 	675 	623 	481 	2,275 	2 	1 	-17 	-17
Pneumovax 23 	256 	117 	375 	339 	1,087 	185 	170 	237 	334 	926 	1 	17 	18
RotaTeq 	222 	168 	210 	196 	797 	211 	172 	180 	227 	791 	-14 	-14 	1 	1
Vaqta 	60 	28 	51 	31 	170 	47 	58 	62 	71 	238 	-56 	-56 	-29 	-27
Hospital Acute Care
Bridion 	299 	224 	320 	355 	1,198 	255 	278 	284 	313 	1,131 	13 	13 	6 	7
Noxafil 	94 	73 	79 	82 	329 	190 	193 	177 	103 	662 	-20 	-22 	-50 	-50
Prevymis 	60 	63 	77 	80 	281 	32 	38 	45 	50 	165 	61 	57 	70 	69
Primaxin 	51 	64 	74 	62 	251 	59 	71 	77 	67 	273 	-8 	-12 	-8 	-8
Cancidas 	55 	43 	50 	65 	213 	61 	67 	62 	58 	249 	13 	11 	-14 	-13
Invanz 	64 	43 	51 	53 	211 	72 	78 	57 	57 	263 	-7 	-4 	-20 	-16
Cubicin 	46 	32 	39 	36 	152 	88 	67 	52 	50 	257 	-27 	-28 	-41 	-40
Zerbaxa 	37 	32 	43 	19 	130 	26 	27 	35 	32 	121 	-42 	-42 	8 	10
Immunology
Simponi 	215 	191 	209 	223 	838 	208 	214 	203 	205 	830 	9 	4 	1 	1
Remicade 	88 	73 	82 	88 	330 	123 	98 	101 	89 	411 	-2 	-5 	-20 	-20
Neuroscience
Belsomra 	79 	84 	81 	83 	327 	67 	76 	80 	83 	306 	1 	-2 	7 	5
Virology
Isentress / Isentress HD 	245 	196 	205 	211 	857 	255 	247 	250 	223 	975 	-5 	-6 	-12 	-11
Zepatier 	55 	39 	28 	45 	167 	114 	108 	83 	66 	370 	-32 	-32 	-55 	-54
Cardiovascular
Zetia 	145 	137 	103 	98 	482 	140 	156 	147 	146 	590 	-33 	-36 	-18 	-19
Vytorin 	53 	39 	47 	43 	182 	97 	76 	57 	54 	285 	-19 	-20 	-36 	-34
Atozet 	122 	115 	111 	105 	453 	94 	92 	97 	108 	391 	-3 	-7 	16 	16
Alliance Revenue - Adempas (4) 53 	79 	83 	65 	281 	42 	51 	50 	60 	204 	8 	8 	38 	38
Adempas (5) 56 	57 	55 	53 	220 	48 	53 	57 	57 	215 	-7 	-11 	3 	2
Diabetes (6)
Januvia 	774 	854 	821 	857 	3,306 	824 	908 	807 	943 	3,482 	-9 	-11 	-5 	-5
Janumet 	503 	490 	506 	472 	1,971 	530 	533 	503 	475 	2,041 	-1 	-1 	-3 	-2
Women's Health
Implanon / Nexplanon 	195 	132 	189 	165 	680 	199 	183 	199 	206 	787 	-20 	-20 	-14 	-13
NuvaRing 	63 	63 	58 	53 	236 	219 	240 	241 	179 	879 	-70 	-70 	-73 	-73
Diversified Brands
Singulair 	155 	100 	82 	124 	462 	191 	160 	152 	195 	698 	-36 	-38 	-34 	-34
Cozaar / Hyzaar 	102 	98 	91 	94 	386 	103 	109 	116 	113 	442 	-17 	-18 	-13 	-11
Arcoxia 	70 	65 	68 	54 	258 	75 	75 	72 	67 	288 	-19 	-18 	-11 	-8
Nasonex 	71 	49 	41 	57 	218 	96 	72 	58 	67 	293 	-14 	-13 	-26 	-24
Follistim AQ 	41 	44 	50 	57 	193 	57 	63 	62 	58 	241 	-2 	-4 	-20 	-20
Other Pharmaceutical (7) 1,194 	1,103 	1,186 	1,228 	4,709 	1,082 	1,203 	1,149 	1,183 	4,615 	4 	2 	2 	3
ANIMAL HEALTH 	1,214 	1,101 	1,220 	1,168 	4,703 	1,025 	1,124 	1,122 	1,122 	4,393 	4 	6 	7 	10
Livestock 	739 	648 	758 	794 	2,939 	611 	671 	726 	777 	2,784 	2 	4 	6 	9
Companion Animals 	475 	453 	462 	374 	1,764 	414 	453 	396 	345 	1,609 	8 	9 	10 	11
Other Revenues (8) 188 	92 	11 	(21) 	270 	128 	176 	180 	213 	696 	-110 	-45 	-61 	-22
2020 	2019 	4Q 	Full Year
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
(6) Total Diabetes sales were $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020 and $1,402 million, $1,480 million, $1,360 million and
$1,472 million in the first, second, third and fourth quarters of 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020 and $1,887 million, $2,037 million, $2,517 million and
$1,928 million in the first, second, third and fourth quarters of 2019, respectively.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
7

-- 8 of 13 --

4Q 2020 	4Q 2019 	% Change 	4Q 2020 	4Q 2019 	% Change 	4Q 2020 	4Q 2019 	% Change
TOTAL SALES (1) $12,514 	$11,868 	5 	$5,631 	$5,199 	8 	$6,882 	$6,669 	3
PHARMACEUTICAL 	11,367 	10,533 	8 	5,247 	4,751 	10 	6,120 	5,782 	6
Oncology
Keytruda 	3,993 	3,111 	28 	2,246 	1,780 	26 	1,747 	1,331 	31
Alliance Revenue - Lynparza (2) 206 	132 	56 	120 	82 	46 	85 	49 	73
Alliance Revenue - Lenvima (2) 158 	124 	28 	90 	70 	27 	69 	53 	29
Emend 	31 	53 	-42 	10 	-102 	31 	42 	-27
Vaccines (3)
Gardasil / Gardasil 9 	998 	693 	44 	546 	252 	117 	452 	441 	2
ProQuad / M-M-R II / Varivax 	488 	481 	2 	345 	358 	-4 	144 	123 	17
Pneumovax 23 	339 	334 	1 	249 	251 	-1 	90 	83 	8
RotaTeq 	196 	227 	-14 	131 	146 	-10 	65 	81 	-20
Vaqta 	31 	71 	-56 	25 	28 	-11 	7 	43 	-85
Hospital Acute Care
Bridion 	355 	313 	13 	172 	152 	13 	183 	162 	13
Noxafil 	82 	103 	-20 	15 	14 	6 	67 	89 	-24
Prevymis 	80 	50 	61 	32 	24 	32 	48 	25 	90
Cancidas 	65 	58 	13 	5 	2 	198 	60 	56 	7
Primaxin 	62 	67 	-8 	62 	67 	-8
Invanz 	53 	57 	-7 	2 	* 	50 	57 	-11
Cubicin 	36 	50 	-27 	10 	13 	-22 	26 	36 	-30
Zerbaxa 	19 	32 	-42 	17 	18 	-7 	2 	14 	-86
Immunology
Simponi 	223 	205 	9 	223 	205 	9
Remicade 	88 	89 	-2 	88 	89 	-2
Neuroscience
Belsomra 	83 	83 	1 	14 	24 	-42 	69 	59 	18
Virology
Isentress / Isentress HD 	211 	223 	-5 	83 	95 	-13 	128 	128
Zepatier 	45 	66 	-32 	22 	23 	-2 	23 	44 	-47
Cardiovascular
Zetia 	98 	146 	-33 	3 	3 	15 	94 	144 	-34
Vytorin 	43 	54 	-19 	3 	4 	-27 	40 	49 	-19
Atozet 	105 	108 	-3 	105 	108 	-3
Alliance Revenue - Adempas (4) 65 	60 	8 	58 	57 	2 	7 	3 	128
Adempas (5) 53 	57 	-7 	53 	57 	-7
Diabetes (6)
Januvia 	857 	943 	-9 	360 	502 	-28 	497 	441 	13
Janumet 	472 	475 	-1 	115 	127 	-9 	356 	348 	2
Women's Health
Implanon / Nexplanon 	165 	206 	-20 	114 	147 	-22 	50 	59 	-14
NuvaRing 	53 	179 	-70 	25 	150 	-83 	28 	29 	-4
Diversified Brands
Singulair 	124 	195 	-36 	4 	5 	-18 	120 	190 	-37
Cozaar / Hyzaar 	94 	113 	-17 	4 	8 	-52 	91 	105 	-14
Nasonex 	57 	67 	-14 	3 	7 	-63 	55 	60 	-9
Follistim AQ 	57 	58 	-2 	24 	22 	9 	33 	36 	-9
Arcoxia 	54 	67 	-19 	54 	67 	-19
Other Pharmaceutical (7) 1,228 	1,183 	4 	410 	377 	9 	818 	809 	1
ANIMAL HEALTH 	1,168 	1,122 	4 	361 	341 	6 	807 	781 	3
Livestock 	794 	777 	2 	165 	177 	-7 	629 	600 	5
Companion Animals 	374 	345 	8 	196 	164 	20 	178 	181 	-2
Other Revenues (8) (21) 	213 	-110 	23 	107 	-78 	(45) 	106 	-142
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(3) Total Vaccines sales were $2,163 million and $1,928 million on a global basis in the fourth quarter of 2020 and 2019, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FOURTH QUARTER 2020
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,412 million and $1,472 million on a global basis in the fourth quarter of 2020 and 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
8

-- 9 of 13 --

Full Year 2020 	Full Year 2019 	% Change 	Full Year 2020 	Full Year 2019 	% Change 	Full Year 2020 	Full Year 2019 	% Change
TOTAL SALES (1) $47,994 	$46,840 	2 	$21,027 	$20,519 	2 	$26,967 	$26,321 	2
PHARMACEUTICAL 	43,021 	41,751 	3 	19,449 	18,953 	3 	23,572 	22,798 	3
Oncology
Keytruda 	14,380 	11,084 	30 	8,352 	6,305 	32 	6,028 	4,779 	26
Alliance Revenue - Lynparza (2) 725 	444 	63 	417 	269 	55 	308 	176 	75
Alliance Revenue - Lenvima (2) 580 	404 	44 	359 	239 	50 	220 	165 	34
Emend 	145 	388 	-63 	18 	183 	-90 	127 	205 	-38
Vaccines (3)
Gardasil / Gardasil 9 	3,938 	3,737 	5 	1,755 	1,831 	-4 	2,184 	1,905 	15
ProQuad / M-M-R II / Varivax 	1,878 	2,275 	-17 	1,378 	1,683 	-18 	500 	592 	-16
Pneumovax 23 	1,087 	926 	17 	727 	679 	7 	359 	247 	46
RotaTeq 	797 	791 	1 	486 	506 	-4 	311 	284 	9
Vaqta 	170 	238 	-29 	103 	130 	-21 	67 	108 	-38
Hospital Acute Care
Bridion 	1,198 	1,131 	6 	583 	533 	10 	615 	598 	3
Noxafil 	329 	662 	-50 	42 	282 	-85 	287 	380 	-24
Prevymis 	281 	165 	70 	119 	84 	41 	162 	81 	101
Primaxin 	251 	273 	-8 	2 	2 	31 	248 	271 	-9
Cancidas 	213 	249 	-14 	7 	6 	9 	207 	242 	-15
Invanz 	211 	263 	-20 	9 	30 	-70 	202 	233 	-13
Cubicin 	152 	257 	-41 	46 	92 	-49 	106 	165 	-36
Zerbaxa 	130 	121 	8 	74 	63 	17 	56 	58 	-2
Immunology
Simponi 	838 	830 	1 	838 	830 	1
Remicade 	330 	411 	-20 	330 	411 	-20
Neuroscience
Belsomra 	327 	306 	7 	81 	92 	-12 	247 	214 	15
Virology
Isentress / Isentress HD 	857 	975 	-12 	326 	398 	-18 	531 	576 	-8
Zepatier 	167 	370 	-55 	60 	118 	-49 	107 	252 	-58
Cardiovascular
Zetia 	482 	590 	-18 	(1) 	14 	-108 	483 	575 	-16
Vytorin 	182 	285 	-36 	12 	16 	-24 	171 	269 	-37
Atozet 	453 	391 	16 	453 	391 	16
Alliance Revenue - Adempas (4) 281 	204 	38 	259 	194 	33 	22 	10 	130
Adempas (5) 220 	215 	3 	220 	215 	3
Diabetes (6)
Januvia 	3,306 	3,482 	-5 	1,470 	1,724 	-15 	1,836 	1,758 	4
Janumet 	1,971 	2,041 	-3 	477 	589 	-19 	1,494 	1,452 	3
Women's Health
Implanon / Nexplanon 	680 	787 	-14 	488 	568 	-14 	192 	219 	-12
NuvaRing 	236 	879 	-73 	110 	742 	-85 	127 	136 	-7
Diversified Brands
Singulair 	462 	698 	-34 	18 	29 	-40 	444 	669 	-34
Cozaar / Hyzaar 	386 	442 	-13 	21 	24 	-13 	365 	418 	-13
Arcoxia 	258 	288 	-11 	258 	288 	-11
Nasonex 	218 	293 	-26 	12 	9 	31 	206 	284 	-27
Follistim AQ 	193 	241 	-20 	84 	103 	-18 	109 	138 	-21
Other Pharmaceutical (7) 4,709 	4,615 	2 	1,555 	1,416 	10 	3,152 	3,204 	-2
ANIMAL HEALTH 	4,703 	4,393 	7 	1,484 	1,306 	14 	3,219 	3,086 	4
Livestock 	2,939 	2,784 	6 	612 	582 	5 	2,327 	2,201 	6
Companion Animals 	1,764 	1,609 	10 	872 	724 	20 	892 	885 	1
Other Revenues (8) 270 	696 	-61 	94 	260 	-64 	176 	437 	-60
Sum of U.S. plus international may not equal global due to rounding.
(3) Total Vaccines sales were $8,258 million and $8,368 million on a global basis for December YTD 2020 and 2019, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FULL YEAR 2020
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $5,588 million and $5,714 million on a global basis for December YTD 2020 and 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
9

-- 10 of 13 --

% Change 	% Change
TOTAL PHARMACEUTICAL 	$10,655 	$9,679 	$11,320 	$11,367 	$43,021 	$9,663 	$10,460 	$11,095 	$10,533 	$41,751 	8 	3
United States (1) 4,714 	4,270 	5,218 	5,247 	19,449 	4,215 	4,807 	5,180 	4,751 	18,953 	10 	3
% Pharmaceutical Sales 	44.2% 	44.1% 	46.1% 	46.2% 	45.2% 	43.6% 	46.0% 	46.7% 	45.1% 	45.4%
Europe (2) 2,543 	2,196 	2,549 	2,709 	9,997 	2,335 	2,301 	2,304 	2,373 	9,314 	14 	7
% Pharmaceutical Sales 	23.9% 	22.7% 	22.5% 	23.8% 	23.2% 	24.2% 	22.0% 	20.8% 	22.5% 	22.3%
China 	846 	811 	990 	888 	3,534 	725 	745 	898 	773 	3,141 	15 	13
% Pharmaceutical Sales 	7.9% 	8.4% 	8.7% 	7.8% 	8.2% 	7.5% 	7.1% 	8.1% 	7.3% 	7.5%
Japan 	789 	847 	805 	847 	3,288 	779 	900 	894 	921 	3,494 	-8 	-6
% Pharmaceutical Sales 	7.4% 	8.8% 	7.1% 	7.5% 	7.6% 	8.1% 	8.6% 	8.1% 	8.7% 	8.4%
Asia Pacific (other than China and Japan) 	613 	555 	601 	603 	2,372 	642 	606 	638 	614 	2,500 	-2 	-5
% Pharmaceutical Sales 	5.8% 	5.7% 	5.3% 	5.3% 	5.5% 	6.6% 	5.8% 	5.8% 	5.8% 	6.0%
Eastern Europe/Middle East/Africa 	490 	416 	419 	365 	1,689 	343 	388 	423 	423 	1,577 	-14 	7
% Pharmaceutical Sales 	4.6% 	4.3% 	3.7% 	3.2% 	3.9% 	3.6% 	3.7% 	3.8% 	4.0% 	3.8%
Latin America 	419 	399 	477 	474 	1,768 	427 	523 	534 	429 	1,914 	10 	-8
% Pharmaceutical Sales 	3.9% 	4.1% 	4.2% 	4.2% 	4.1% 	4.4% 	5.0% 	4.8% 	4.1% 	4.6%
Canada 	212 	160 	216 	194 	782 	177 	179 	211 	216 	783 	-10 	0
% Pharmaceutical Sales 	2.0% 	1.7% 	1.9% 	1.7% 	1.8% 	1.8% 	1.7% 	1.9% 	2.0% 	1.9%
Other (1) 29 	25 	45 	40 	142 	20 	11 	13 	33 	75 	21 	89
% Pharmaceutical Sales 	0.3% 	0.3% 	0.4% 	0.4% 	0.3% 	0.2% 	0.1% 	0.1% 	0.3% 	0.2%
2020 	2019
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
4Q 	Full Year	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Alliance revenue related to Adempas attributable to the United States has been reclassified from Other.
(2) Europe primarily represents all European Union countries and the European Union accession markets.
2Q 	3Q 	4Q 	Full Year
10

-- 11 of 13 --

OTHER (INCOME) EXPENSE, NET
4Q20 	4Q19
Full Year
2020
Full Year
2019
Interest income 	(11)	$ 	(50)	$ 	(59)	$ 	(274)	$
Interest expense 	206 	220 	831 	893
Exchange losses 	56 	21 	145 	187
Income from investments in equity securities, net (1) (375) 	(119) 	(1,338) 	(170)
Net periodic defined benefit plan (credit) cost other than service cost 	(80) 	(136) 	(339) 	(545)
Other, net 	(54) 	(159) 	(126) 	48
Total 	(258)	$ 	(223)	$ 	(886)	$ 	139	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds
are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
11

-- 12 of 13 --

As Reported 2020 	Impact of non-GAAP reporting
changes
As Recast 2020
Full Year 2020
Cost of sales 	$ 12,332 	$ 719 	$ 11,613
Selling, general and administrative 	9,486 	9,486
Research and development 	9,231 	11 	9,220
Other (income) expense, net 	(916) 	(1,292) 	376
Income Before Taxes 	17,861 	562 	17,299
Income Tax Provision 	2,764 	186 	2,578
Net Income 	15,097 	376 	14,721
Net Income Attributable to Merck & Co., Inc. 	15,082 	376 	14,706
Earnings per Common Share Assuming Dilution 	$ 5.94 	$ 0.15 	5.79	$
Tax Rate 	15.5% 	14.9%
First Quarter 2020
Cost of Sales 	$ 2,948 	$ 111 	$ 2,837
Selling, General and administrative 	2,266 	2,266
Research and development 	2,155 	3 	2,152
Other (income) expense, net 	82 	(87) 	169
Income Before Taxes 	4,606 	(27) 	4,633
Income Tax Provision 	784 	2 	782
Net Income 	3,822 	(29) 	3,851
Net Income Attributable to Merck & Co., Inc. 	3,822 	(29) 	3,851
Earnings Per Common Share Assuming Dilution 	1.50	$ 	(0.01)	$ 	1.51	$
Tax Rate 	17.0% 	16.9%
Second Quarter 2020
Cost of Sales 	$ 2,852 	$ 319 	$ 2,533
Selling, General and administrative 	2,204 	2,204
Research and development 	2,157 	2 	2,155
Other (income) expense, net 	(437) 	(511) 	74
Income Before Taxes 	4,096 	190 	3,906
Income Tax Provision 	604 	74 	530
Net Income 	3,492 	116 	3,376
Net Income Attributable to Merck & Co., Inc. 	3,484 	116 	3,368
Earnings Per Common Share Assuming Dilution 	1.37	$ 	0.05	$ 	1.32	$
Tax Rate 	14.7% 	13.6%
Third Quarter 2020
Cost of Sales 	$ 3,158 	$ 138 	$ 3,020
Selling, General and administrative 	2,228 	2,228
Research and development 	2,273 	3 	2,270
Other (income) expense, net 	(311) 	(346) 	35
Income Before Taxes 	5,203 	205 	4,998
Income Tax Provision 	772 	56 	716
Net Income 	4,431 	149 	4,282
Net Income Attributable to Merck & Co., Inc. 	4,427 	149 	4,278
Earnings Per Common Share Assuming Dilution 	1.74	$ 	0.06	$ 	1.68	$
Tax Rate 	14.8% 	14.3%
Fourth Quarter 2020
Cost of Sales 	$ 3,373 	$ 151 	$ 3,222
Selling, General and administrative 	2,789 	2,789
Research and development 	2,648 	3 	2,645
Other (income) expense, net 	(253) 	(348) 	95
Income Before Taxes 	3,957 	194 	3,763
Income Tax Provision 	605 	54 	551
Net Income 	3,352 	140 	3,212
Net Income Attributable to Merck & Co., Inc. 	3,350 	140 	3,210
Earnings Per Common Share Assuming Dilution 	1.32	$ 	0.05	$ 	1.27	$
Tax Rate 	15.3% 	14.6%
Merck is providing certain 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis
of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results
and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting
purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance
with GAAP.
MERCK & CO., INC.
NON-GAAP REPORTING CHANGES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 5
Beginning in 2021, the Company will be changing the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results
excluded the amortization of intangible assets recognized in connection with business acquisitions, but did not exclude the amortization of intangibles originating
from collaborations, asset acquisitions or licensing arrangements. In 2021, Merck’s non-GAAP results will no longer differentiate between the nature of
intangibles amortization and will exclude all amortization of intangible assets. Also, beginning in 2021, Merck’s non-GAAP results will exclude gains and losses
on investments in equity securities. These amounts are difficult to predict and can fluctuate significantly period to period affecting comparability of results. Non-
GAAP results for the quarterly and annual periods of 2020 will be recast to conform to the new presentation. The table below provides details of the effects of
these changes to the Company's non-GAAP results for the full year of 2020 and by quarter as will be presented in 2021 reporting.
Non-GAAP Results
12

-- 13 of 13 --